about
Structural basis for carbapenem-hydrolyzing mechanisms of carbapenemases conferring antibiotic resistanceCarbapenemsThe pharmacokinetics and pharmacodynamics of the carbapanemes: focus on doripenemCharacteristics of carbapenemase-producing Klebsiella pneumoniae as a cause of neonatal infection in Shandong, ChinaIn vivo pharmacodynamic activity of tomopenem (formerly CS-023) against Pseudomonas aeruginosa and methicillin-resistant Staphylococcus aureus in a murine thigh infection model.Novel carbapenem antibiotics for parenteral and oral applications: in vitro and in vivo activities of 2-aryl carbapenems and their pharmacokinetics in laboratory animals.Evaluation of updated interpretative criteria for categorizing Klebsiella pneumoniae with reduced carbapenem susceptibility.Antibiotic Susceptibility Pattern of ESβL Producing Klebsiella pneumoniae Isolated from Urine Samples of Pregnant Women in Karnataka.Doripenem in hospital infections: a focus on nosocomial pneumonia, complicated intra-abdominal infections, and complicated urinary tract infections.Efficacy of human-simulated exposures of tomopenem (formerly CS-023) in a murine model of Pseudomonas aeruginosa and methicillin-resistant Staphylococcus aureus infectionClinically relevant plasma concentrations of colistin in combination with imipenem enhance pharmacodynamic activity against multidrug-resistant Pseudomonas aeruginosa at multiple inocula.Comparable outcomes for β-lactam/β-lactamase inhibitor combinations and carbapenems in definitive treatment of bloodstream infections caused by cefotaxime-resistant Escherichia coli or Klebsiella pneumoniae.Synergistic killing of multidrug-resistant Pseudomonas aeruginosa at multiple inocula by colistin combined with doripenem in an in vitro pharmacokinetic/pharmacodynamic model.Meropenem-clavulanic acid shows activity against Mycobacterium tuberculosis in vivo.Prevalence and Fate of Carbapenemase Genes in a Wastewater Treatment Plant in Northern China.New Structural Templates for Clinically Validated and Novel Targets in Antimicrobial Drug Research and Development.Dosing nomograms for attaining optimum concentrations of meropenem by continuous infusion in critically ill patients with severe gram-negative infections: a pharmacokinetics/pharmacodynamics-based approachMechanistic insights into the bifunctional non-heme iron oxygenase carbapenem synthase by active site saturation mutagenesisSafety of high-dose doripenem in adult patients with cystic fibrosisSynthesis of labeled meropenem for the analysis of M. tuberculosis transpeptidases.Epidemiology and genetics of VIM-type metallo-β-lactamases in Gram-negative bacilli.In vitro activity studies of doripenem and two other carbapenems tested against Pseudomonas aeruginosa and other non-fermentative bacilli.Antibiotic Dosing in Patients With Acute Kidney Injury: "Enough But Not Too Much".Late-onset sepsis in preterm infants: update on strategies for therapy and prevention.Travel-acquired ESBL-producing Enterobacteriaceae: impact of colonization at individual and community levelComparison of in vitro activities of meropenem productions on Klebsiella pneumoniae isolated from hospitalized patients.The rapid spread of carbapenem-resistant Enterobacteriaceae.QM/MM simulations as an assay for carbapenemase activity in class A β-lactamases.Quorum sensing-controlled buoyancy through gas vesicles: Intracellular bacterial microcompartments for environmental adaptationPrevalence and Risk Factors associated with Extended Spectrum Beta Lactamase Producing Escherichia coli and Klebsiella pneumoniae Isolates in Hospitalized Patients in Kashan (Iran).Worldwide experience with the use of doripenem against extended-spectrum-beta-lactamase-producing and ciprofloxacin-resistant Enterobacteriaceae: analysis of six phase 3 clinical studiesSolid-state stability study of meropenem - solutions based on spectrophotometric analysis.In vitro study of elution kinetics and bio-activity of meropenem-loaded acrylic bone cement.Mutational analysis of the thienamycin biosynthetic gene cluster from Streptomyces cattleya.In vitro activity of doripenem against Burkholderia pseudomallei.Predictability of doripenem susceptibility in Acinetobacter baumannii isolates based on other carbapenem susceptibilities and bla OXA gene status.Activity of Meropenem-Vaborbactam in Mouse Models of Infection Due to KPC-Producing Carbapenem-Resistant Enterobacteriaceae.Modified Penicillin Molecule with Carbapenem-Like Stereochemistry Specifically Inhibits Class C β-Lactamases.In vivo transfer and microevolution of avian native IncA/C2blaNDM-1-carrying plasmid pRH-1238 during a broiler chicken infection study.Synthesis and Characterization of Cefotaxime Conjugated Gold Nanoparticles and Their Use to Target Drug-Resistant CTX-M-Producing Bacterial Pathogens.
P2860
Q28084628-0EDCF365-2B4C-4843-B7A9-DF03642A93FEQ28286055-7CACA5FA-4924-44D8-8FC6-D02DB6EEAD23Q28289744-38B5D2FC-06F3-466B-96B6-B9C59AB422E0Q33597897-4FB37A8B-DF5C-47AB-9A32-E68B50F28224Q34309420-6E43C075-9006-4F47-BD4B-191F6ABF83AEQ34311384-C1BE959C-5906-4987-9556-3B22DB01553FQ34433108-E710C5D8-DE5F-4A69-A619-48401333CD9FQ34617972-389D49C0-FF60-4ADF-BDA6-EE85BECB344BQ35026526-8F312995-BCF0-455B-A3A3-3DF3CF845003Q35364071-01C27BA5-38C4-44FA-934A-D668CC51BE37Q35364351-19EBDFF9-B989-4BFC-B837-55CA52E027F1Q35552650-40084A22-59AE-4510-899D-F8803B54C5BEQ35598403-447F4DD6-7945-4BA8-8325-02B500AB8AE7Q36018749-772AC39E-40A6-43C5-BE9A-4E58CAFB03C2Q36029984-6C858828-1EB9-4245-AA0C-67F06601F55DQ36153263-F3F81CAB-0D34-413F-8E81-05E78416BBFAQ36396195-D7A018F7-953F-4B6E-B9FF-E93E50E52D91Q36932752-88DEB57C-8554-4BAD-ADA9-EFB87D952B9CQ36967193-BDEF78F2-8608-4840-B65E-50EA797571ACQ37462494-DDD4AA45-596C-4305-BCCA-075856CD8343Q37859396-DAEB248B-1B5C-4B8F-B70A-84CF08A2A3A6Q37974745-5944CB82-208D-4F91-874C-B1541E4BC1EEQ38261172-23E5651B-0332-43AE-850B-9889FDEBB1B2Q38347714-6D9F65BE-6FBD-479D-81BA-78D6F2B47A6BQ38776963-3FA24B54-F260-461E-86AC-97F0ABEAB75DQ38865064-52A713DC-FEAA-4D41-ACB4-C5429B28DCA7Q39027434-51D22AA8-A994-4660-A4D2-6BB0CF894369Q39112147-7E3BE36B-8181-4219-A329-58A45D1A3ABEQ39632118-D46F6442-94DF-4069-AC22-DB7EA849885DQ39814783-258F835B-94BB-4552-9105-6FA8555E3A33Q40337526-197D95FE-F55D-4614-A7F4-D29F40F645AAQ41981719-3CBE79F6-BFD2-4F29-8E84-506BAE828ECDQ42321251-E03B023A-A5FE-4F9B-B2A1-571C959398D7Q42706319-9CD14935-BA68-4AB4-ABEC-9FA2B14CF583Q43102666-E289DE25-786D-4201-B6BC-BEEDE840D253Q43119954-1C874F2F-51BA-4DB1-8C12-AB2551E2F0ADQ47647043-AA16BE65-00C3-4EBB-A4AF-7DF2DE61A971Q47859619-4AEC4CB4-DB72-4FF3-A294-79096463E623Q49923903-158FAAD4-96B8-4F22-9AC4-BD097301A1F4Q53525114-E3BA4A76-D613-4C84-8B99-4F812F2E4AA6
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on January 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Carbapenems: a potent class of antibiotics.
@en
Carbapenems: a potent class of antibiotics.
@nl
type
label
Carbapenems: a potent class of antibiotics.
@en
Carbapenems: a potent class of antibiotics.
@nl
prefLabel
Carbapenems: a potent class of antibiotics.
@en
Carbapenems: a potent class of antibiotics.
@nl
P2860
P356
P1476
Carbapenems: a potent class of antibiotics.
@en
P2093
David P Nicolau
P2860
P356
10.1517/14656566.9.1.23
P407
P577
2008-01-01T00:00:00Z